RxDoctor Payments Data

Rohini Samudralwar, MD

Neurology · Houston, TXNPI 1720421373

Payments from drug & device makers

$110,570in general payments, 2019–2025

Across 287 payments — averaging $385.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$64K
  • EMD Serono, Inc.$24K
  • TG Therapeutics, Inc.$8K
  • Amgen$6K
  • Genentech USA, Inc.$5K
  • AstraZeneca$2K
  • plus $2K from 10 others

What the payments were for

  • Consulting fees$50,90346%
  • Speaking & faculty fees$48,47544%
  • Travel & lodging$3,3263%
  • Food & beverage$7,7917%
  • Education$760%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$110,570 in reported general payments places this provider in the 85th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$29,495
Medicare patients
169
Services billed
345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab17$248,722
Kesimpta PenOfatumumab27$248,396
AubagioTeriflunomide20$183,919
RebifInterferon Beta-1a/Albumin11$163,032
CopaxoneGlatiramer Acetate25$143,473
Rebif RebidoseInterferon Beta-1a/Albumin12$111,561
BriviactBrivaracetam11$18,054
Emgality PenGalcanezumab-Gnlm12$8,528
RasuvoMethotrexate/Pf13$6,243
Dalfampridine ErDalfampridine20$4,654
Modafinil22$3,482
Baclofen84$2,228
Lacosamide17$1,556
Tizanidine Hcl13$1,049
Gabapentin38$1,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$421$183,91920 claims
EMD Serono, Inc.Rebif$23,527$163,03211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →